Related Experiment Videos
Management issues in severe childhood epilepsies
1University Hospital of Wales, Health Park, Cardiff, UK.
Insights
Newer antiepileptic drugs (AEDs) show promise for severe childhood epilepsies, with specific drugs like lamotrigine and vigabatrin demonstrating efficacy in certain conditions. Further comparative trials are needed for optimal treatment selection.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Epileptology
Background:
- Severe epilepsies in childhood present significant management challenges.
- Existing treatments for certain severe childhood epilepsy syndromes remain inadequate.
Purpose of the Study:
- To review the efficacy of newly developed antiepileptic drugs (AEDs) for severe childhood epilepsies.
- To identify potential therapeutic advances for refractory epilepsy syndromes.
Main Methods:
- Literature review of available information on newly developed AEDs.
- Analysis of drug efficacy data for specific childhood epilepsy types.
Main Results:
- Vigabatrin and lamotrigine show efficacy in West syndrome and Lennox-Gastaut syndrome.
- Lamotrigine is effective for astatic seizures and severe myoclonic epilepsy.
- Vigabatrin is effective for non-idiopathic partial and secondary generalized epilepsies.
- Felbamate shows efficacy in Lennox-Gastaut syndrome.
- Vigabatrin may exacerbate myoclonic attacks in some cases.
Conclusions:
- Newer AEDs offer therapeutic options for several severe childhood epilepsy syndromes.
- Specific AEDs like vigabatrin, lamotrigine, and felbamate have demonstrated utility.
- Comparative trials of newer AEDs are crucial for guiding clinical practice.
Abstract:
The severe epilepsies of childhood are described briefly and information available on the efficacy of newly developed antiepileptic drugs (AEDs) in their control is reviewed. Therapeutic advances are awaited for early infantile epileptic encephalopathy, early myoclonic encephalopathy, progressive myoclonus epilepsies and Kojewnikow syndrome. West syndrome may respond to vigabatrin, and less predictably to lamotrigine. Lamotrigine can be helpful for severe myoclonic epilepsy and myoclonic absences. Astatic seizures may be dramatically controlled by lamotrigine, whereas vigabatrin may worsen myoclonic attacks. In the Lennox-Gastaut syndrome, the efficacy of felbamate has been demonstrated by a controlled trial; vigabatrin and lamotrigine can also be helpful. Non-idiopathic partial and secondary generalized epilepsies are responsive to vigabatrin in a useful percentage of cases, and some children improve with felbamate, lamotrigine or striripentol. A trial which compares the efficacies of the newer AEDs against each other could provide very useful information for the clinician.